Thye Dirk's Form 4 filing
Quince Therapeutics, Inc. (QNCX) · filed Sep 3, 2024
- Accession no.
- 0001415889-24-022702
- Filed
- Sep 3, 2024
- Trade date
- Aug 29-30, 2024
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $107.4K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Thye DirkCIK 0001638945 | Director, Officer (CEO AND CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 29, 2024 | Common Stock | PPurchaseAcquired | +77,500 | $0.69 | +$53,475 | 766,941 | Direct | |
| Aug 30, 2024 | Common Stock | PPurchaseAcquired | +77,000 | $0.70 | +$53,900 | 843,941 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.